The Evolution of Insulin and How it Informs Therapy and Treatment Choices
Open accessThe DOI matches its Crossref record; 79 of the 82 references it cites were found in a registry or an index.
Abstract
Insulin has been available for the treatment of diabetes for almost a century, and the variety of insulin choices today represents many years of discovery and innovation. Insulin has gone from poorly defined extracts of animal pancreata to pure and precisely controlled formulations that can be prescribed and administered with high accuracy and predictability of action. Modifications of the insulin formulation and of the insulin molecule itself have made it possible to approximate the natural endogenous insulin response. Insulin and insulin formulations had to be designed to produce either a constant low basal level of insulin or the spikes of insulin released in response to meals. We discuss how the biochemical properties of endogenous insulin were exploited to either shorten or extend the time-action profiles of injectable insulins by varying the pharmacokinetics (time for appearance of insulin in the blood after injection) and pharmacodynamics (time-dependent changes in blood sugar after injection). This has resulted in rapid-acting, short-acting, intermediate-acting, and long-acting insulins, as well as mixtures and concentrated formulations. An understanding of how various insulins and formulations were designed to solve the challenges of insulin replacement will assist clinicians in meeting the needs of their individual patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 2. Structure of human insulin. A: Amino acid sequence of human insulin. B: Three-dimensional structure of insulin monomer (A-chain in purple; B-chain in green; protein data bank [PDB] ID = 1LPH), insulin dimer (PDB ID = 1LPH), and insulin hexamer (comprised of 3 dimers and 2 Zn2+) (PDB ID = 2INS). (https://www.rcsb.org/pdb/static.do?p=general_information/about_pdb/index.html); 1LPH, 2INS=PDB ID for respective structures)](https://figures.cochat.ai/paper-figures/47a9baa04bb54a408b711fbf0d4e6807/the-evolution-of-insulin-and-how-it-informs-therapy-and-treatment-choices-figure-2.jpg)
















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of the insulin delivery method (MDI vs CSII), glycemic control metrics, including A1C and CGM TIR, hypoglycemic events, QoL, and patient satisfaction are substantially improved when MDI or CSII is augmented with CGM, with better results when CSII is combined with CGM or integrated into AID systems, compared with using CGM.158,160,1129–1131”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Towards a goal of reducing the need for multiple daily injections, the first long-acting insulin was developed in the 1930s by H. C. Hagedorn. It was a suspension protamine zinc insulin that was based on the discovery that insulin action could be prolonged by adding protamine obtained from river trout semen106. The action of protamine zinc insulin lasted 24–36 h.”
From 100 years of insulin: celebrating the past, present and future of diabetes therapy (2021) · cites this paper as [106]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These insulins reduce postprandial hyperglycemia but have otherwise not been shown to reduce HbA 1c or hypoglycemia to a greater extent than rapid-acting analogs (3).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Basal insulin analogs were designed with prolonged duration of action and reduced pharmacodynamic variability compared with protamine-based (NPH) human insulin, while rapid-acting analogs were introduced with quicker onset and shorter duration than short-acting (”
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Heise, T., Nosek, L., Rønn, B. B., Endahl, L., Heinemann, L., Kapitza, C., & Draeger, E. (2004) · Diabetes · doi:10.2337/diabetes.53.6.1614 · Cited by 614
Bliss, M. (1982) · doi:10.1007/978-1-349-09612-1 · Cited by 524
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448 · cited 1×
“After injection and dilution of the phenolic preservative in the SC space, the dihexamers selfassociate, forming multihexamer complexes (60).”
BackgroundThe Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 429 · cited 1×
“The fatty acyl side chain also enables binding to serum albumin, a long-lived plasma protein, thus slowing the disposition of detemir to peripheral tissues and clearance from the body (53).”
BackgroundBecker, R. H. A., Dahmen, R., Bergmann, K., Lehmann, A., Jax, T., & Heise, T. (2015) · Diabetes Care · doi:10.2337/dc14-0006 · Cited by 407 · cited 1×
“A 3-fold concentrated version of insulin glargine was developed to prolong the duration of action when the results of 2 preliminary studies showed less diurnal variation in glucose-lowering activity with U-300 compared to the same dose of U-100 glargine (46).”
ResultGlucose Sensing in Pancreatic β-Cells
Schuit, F. C., Huypens, P., Heimberg, H., & Pipeleers, D. G. (2001) · Diabetes · doi:10.2337/diabetes.50.1.1 · Cited by 405
Human Insulin from Recombinant DNA Technology
Johnson, I. S. (1983) · Science · doi:10.1126/science.6337396 · Cited by 401
Cited by
Items 101–200 of 288
Recent Trends in Peptide Drug Discovery and Development
Madge, H. Y. R., & Muttenthaler, M. (2024) · Royal Society of Chemistry eBooks · doi:10.1039/9781837674541-00023 · Cited by 6
Besançon, S., Haynes, A., Togo, A., Sandy, J., Maniam, J., Traoré, S. A., Djéneba, S., de Beaufort, C. E., Perolini, M. C., Gastaldi, G., et al. (2025) · Diabetic Medicine · doi:10.1111/dme.70007 · Cited by 6
Assessing the Structural and Functional Similarity of Insulin Glargine Biosimilars
Vishwakarma, G., Nupur, N., & Rathore, A. S. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211058482 · Cited by 6
A mixture of poly-γ-glutamic acid and levan ameliorates obesity in high fat diet-induced mice
Jang, K., & Kim, M. (2022) · Food Science and Biotechnology · doi:10.1007/s10068-022-01037-8 · Cited by 6
“Insulin is a hormone to control blood sugar level released from pancreas and indicates high concentration in obesity (Hirsch et al., 2020).”
BackgroundInsulin Therapy in Small Animals, Part 1: General Principles
Fleeman, L. M., & Gilor, C. (2023) · Veterinary Clinics of North America Small Animal Practice · doi:10.1016/j.cvsm.2023.02.002 · Cited by 6
Truncated CD19 as a selection marker for the isolation of stem cell-derived β-cells
Huang, H., Gao, R., Zhang, D., Nian, C., Martzke, W., Shapiro, A. M. J., Kin, T., Tahamtani, Y., & Lynn, F. C. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052376 · Cited by 6
Insulin purification—Innovation continuum via synthesis of fundamentals, technology, and modeling
Roush, D. J., Iammarino, M. J., Chmielowski, R., Insaidoo, F. K., McCoy, M. A., Ortigosa, A. D., & Rauscher, M. A. (2023) · Biotechnology and Bioengineering · doi:10.1002/bit.28427 · Cited by 6
A Hybrid Automata Approach for Monitoring the Patient in the Loop in Artificial Pancreas Systems
Beneyto, A., Puig, V., Bequette, B. W., & Vehí, J. (2021) · Sensors · doi:10.3390/s21217117 · Cited by 6
Impact of structure and formulation changes on the function of insulin products
Yang, Y., Shahinozzaman, M., Shin, H., Bupp, S., & Sourbier, C. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1601119 · Cited by 5
“…data, such as pharmacokinetics (PK) and pharmacodynamics (PD), which are used to de fi ne the time-action pro fi le of insulin products [ (44), Tables 3 – 5]: i) onset of action (the time it takes for the blood glucose to lower after injection); ii) time to peak (the time taken to reach…”
InfluentialMolecular engineering of designer diabetes therapeutics
DeWolf, E. L., Webber, B., & Webber, M. J. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114705 · Cited by 5
Garige, M., Ghosh, S., Roelofs, B., Rao, V. A., & Sourbier, C. (2023) · Methods and Protocols · doi:10.3390/mps6020033 · Cited by 5
“Insulin analogs such as insulin glargine, insulin lispro, and insulin aspart differ due to modifications of a few amino acids: for insulin glargine, asparagine A21 has been changed to glycine A21 and has two additional arginine residues in B30 and B31; for insulin lispro, proline B28 has been changed to lysine B28 and…”
BackgroundAustralasian Anaesthesia 2023: Invited papers and selected continuing education lectures
[editor], D. M. (2023) · Australian and New Zealand College of Anaesthetists eBooks · doi:10.60115/11055/1178 · Cited by 5
Challenge of diabetes mellitus and researchers’ contributions to its control
Odularu, A. T., & Ajibade, P. A. (2021) · Open Chemistry · doi:10.1515/chem-2020-0153 · Cited by 5
“gov/compound/ Insulin-human [53] Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE.”
BackgroundInfluentialResident opinions of diabetes management in training: a survey
Healy, A. M., Uhrig, J. L., Shubrook, J. H., Aung, N. L., & Sadhu, A. (2021) · Journal of Osteopathic Medicine · doi:10.1515/jom-2021-0035 · Cited by 5
“Examples of newer diabetes management drugs include glucagon like peptide receptor agonists (GLP-1RA), sodium glucose transporter-2 inhibitors (SGLT-2i), and new insulin analogs [8, 9].”
BackgroundBergenstal, R. M., Bode, B. W., Bhargava, A., Wang, Q., Knights, A. W., & Chang, A. M. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01476-4 · Cited by 5
“insulin analogues such as insulin lispro, aspart, and glulisine have improved control of PPG [4, 5]; however, the time-action of these may not be fast enough to match carbohydrate absorption [6, 7].”
BackgroundPeng, B., Zhang, Y., Cheng, L., Zhang, Y., Lei, X., Leng, W., Wang, J., Wu, S., Wu, X., & Zheng, Y. (2023) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/170224 · Cited by 5
Horiguchi, M., Yoshihara, K., Watanabe, K., Tsurudome, Y., Mizukami, Y., & Ushijima, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313145 · Cited by 3
Varga, M., Spendal, M., Sigh, J., Søeborg, T., & Nielsen, N. J. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2389637 · Cited by 4
How to improve the quality of euglycemic glucose clamp tests in long-acting insulin studies
Yi, Y., Kuang, F., Zhu, X., Li, L., Huang, Y., Liu, Y., & Yu, X. (2025) · Trials · doi:10.1186/s13063-025-08749-2 · Cited by 4
Choe, J., Belmonte, P. J., Crotts, S. B., Nguyen, T., Friedman, D. J., Zastrow, A. L., Rajcula, M. J., Hammer, B., Wilhelm, C., Shapiro, M. J., et al. (2025) · Journal of Clinical Investigation · doi:10.1172/jci181207 · Cited by 4
“Recent advances for managing T1D have largely focused on improved insulin delivery, including long-lasting insulin formulations (4) and open-or closed-loop pump systems (5, 6).”
Lessons Learned from Regulatory Submissions Involving Endogenous Therapeutic Analyte Bioanalysis
Yu, C., Jiang, W., Matta, M. K., Wang, R., Haidar, S. H., & Seo, H. (2023) · Bioanalysis · doi:10.4155/bio-2023-0209 · Cited by 4
Sloan, L. A., CHENG, A. Y. Y., Escalada, J., Haluzík, M., & Mauricio, D. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15425 · Cited by 4
Insulin’s Legacy: A Century of Breakthroughs and Innovation
Hadid, S. A., Zhang, E., Frishman, W. H., & Brutsaert, E. F. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000680 · Cited by 4
Abdelwaly, E. A., Mohamed, A. A., El-Kosasy, A. M., & Ayad, M. F. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5292 · Cited by 4
White, J., & Corwin, N. (2022) · Journal of Health Politics Policy and Law · doi:10.1215/03616878-10041149 · Cited by 4
Harmonised Methods for Detection of Insulin Immunogenicity
Sathiya, V., & Kumar, V. (2024) · International Journal of Pharmaceutical Investigation · doi:10.5530/ijpi.14.2.38 · Cited by 4
Triple Calcium Binding Stoichiometry in the Monoclinic Crystal Form of Protracted Insulin
Ayan, E. B., Engilberge, S., Yokoi, S., Orlans, J., de Sanctis, D., Basu, S., Mathieu, E., Kepçeoğlu, A., Mitsutake, A., & DeMirci, H. (2025) · Small Structures · doi:10.1002/sstr.202500398 · Cited by 3
Impact of Inhaled Insulin Therapy on Hypoglycemia
Levy, C. J., & Seaquist, E. R. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251381294 · Cited by 3
“22 – 24 Given their delayed onset and extended duration of action, 25,26 as well as the risk for dosing errors, RAA and ultra-RAA formulations with durations of action of 4 – 7 h are still less than ideal for reducing hypoglycemia.”
Ray, S. D., He, L. L., Rottersmann, S., Hand, C., Leo, M. D., Chunilall, A., Gray, I. G., Siu, N. T., Jong, S., Sirois, N., et al. (2026) · Diabetology · doi:10.3390/diabetology7090176 · Cited by 3
The evolution of type 1 diabetes mellitus care
Bulgakova, S. V., Dolgikh, Y. A., Sharonova, L. A., Kosareva, O. V., Treneva, E. V., Kurmaev, D. P., Lebedeva, E. A., & Galkin, R. A. (2023) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2023-12-3-46-53 · Cited by 4
Atiyeh, H. M., Alosta, M. R., Othman, E. H., Khirfan, R., & Hamdan, F. R. (2024) · The Science of Diabetes Self-Management and Care · doi:10.1177/26350106241279813 · Cited by 3
Management of Type 1 Diabetes in Children in the Outpatient Setting
Jackson, S. C., Creo, A. L., & Nofal, A. A. (2022) · Pediatrics in Review · doi:10.1542/pir.2020-001388 · Cited by 3
Paavola, C. D., Felippis, M. R. D., Allen, D. P., Garg, A. K., Sabatowski, J. L., Juneja, R., & Baldwin, D. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-30023-3_16 · Cited by 3
Self-citationKruger, D. F., MAGWIRE, M. L., & Urquhart, S. (2024) · Journal of the American Association of Nurse Practitioners · doi:10.1097/jxx.0000000000001065 · Cited by 3
Anti-diabetic Biologicals: Exploring the Role of Different Analytical Techniques
Yaseen, Z., Nandave, M., & Sharma, L. K. (2025) · Critical Reviews in Analytical Chemistry · doi:10.1080/10408347.2025.2472793 · Cited by 3
“[32] Long-acting analogues like glargine (A21 glycine substitution and arginine addition at the B chain) form a depot for sustained release, while detemir and degludec increase albumin binding or feature fatty acid conjugation to prolong action.”
Javanbakht, S., Poursadegh, H., Darvishi, S., Mohammadzadeh, A., Saboury, A., Joulaei, M., & Mohammadi, R. (2025) · Hybrid Advances · doi:10.1016/j.hybadv.2025.100462 · Cited by 3
Bereda, G. (2022) · Diabetes and Islet Biology · doi:10.31579/2641-8975/030 · Cited by 3
Endocrinology: past, present and future
Verbovoy, A. F., Dolgikh, Y. A., Verbovaya, N. I., & Galkin, R. A. (2022) · Endocrinology News Opinions Training · doi:10.33029/2304-9529-2022-11-3-37-46 · Cited by 4
100 Years of insulin: A chemical engineering perspective
Bequette, B. W. (2023) · Korean Journal of Chemical Engineering · doi:10.1007/s11814-022-1308-8 · Cited by 3
Molecular Research on Diabetes
Puddu, A., & Maggi, D. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051873 · Cited by 3
Bruns, F., Fender, A. C., Poppenborg, T., Dudley, S. C., & Dobrev, D. (2025) · Cardiovascular Research · doi:10.1093/cvr/cvaf252 · Cited by 2
Chowdhury, S. A., Shin, G. Y., Lee, S. E., Han, S., Sk, K., Lee, Y.-K., & Park, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-63234-3 · Cited by 2
Clinical Translation of Porcine Islets for Treating Type 1 Diabetes
Aggarwal, S., Pepper, A., & Korbutt, G. (2022) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2022.100354 · Cited by 1
Cloning and Extracellular Expression of Glargine in Pichia pastoris
Hardianto, D., Martius, E., Rostinawati, T., Safarrida, A., Royani, J. I., Assyifa, F., & Laziba, D. (2023) · HAYATI Journal of Biosciences · doi:10.4308/hjb.31.2.248-255 · Cited by 2
“…modifies human insulin by extending the C terminus of the B chain by adding two arginine residues after the B30 position and replacing asparagine with glycine at the A21 position (Sleigh 1998; Tibaldi 2008; Hilgenfeld et al. 2014; Gururaj Setty et al. 2016; Shen et al. 2019; Hirsch et al. 2020).”
BackgroundRenda, S., & Freeman, J. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2328511 · Cited by 2
“Since its first therapeutic administration in 1922 [2], insulin therapy has continued to evolve, with preparations becoming more physiologic over time [3].”
BackgroundModulation of insulin receptor activation through controlled folding of peptide ligands
Li, W., Dao, Y., Lin, T., Austin, M. J., Lin, N.-P., & Chou, D. H. (2025) · Organic & Biomolecular Chemistry · doi:10.1039/d5ob00363f · Cited by 2
The basics of noninvasive methods
Rydosz, A. M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99887-1.00002-9 · Cited by 2
Brown, L. R. (2022) · Springer eBooks · doi:10.1007/978-3-030-73317-9_25-1 · Cited by 2
Pharmacoeconomic evaluation of insulin aspart and glargine in type 1 and 2 diabetes mellitus in Iran
Nosrati, M., Fariman, S., Saiyarsarai, P., & Nikfar, S. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01209-1 · Cited by 2
Raza, A., Ahmed, I., Fawwad, A., Fatima, F., Nangrejo, R., & Soban, M. (2023) · Pakistan Journal of Pharmaceutical Sciences · doi:10.36721/pjps.2023.36.4.reg.1085-1088.1 · Cited by 2
An Overview of Insulin Therapy in the Management of Diabetes Mellitus
Hayes, M. J. (2023) · Home Healthcare Now · doi:10.1097/nhh.0000000000001216 · Cited by 2
“By the end of 1923, developments within the pharmaceutical industry resulted in the large-scale production of insulin (Hirsch et al., 2020).”
BackgroundEvolution of biosynthetic human insulin and its analogues for diabetes management
Francis, D., Chacko, A. M., Anoop, A., Nadimuthu, S., & Venugopal, V. (2024) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.06.004 · Cited by 2
Rättö, H., Nurminen, M., & Aaltonen, K. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-12010-y · Cited by 2
Xiao, D., Weng, J., Zhang, L., Xing, C., Yan, W., & Chen, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0310497 · Cited by 2
Bal, T. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01919-y · Cited by 2
“Due to destruction of the beta-cells, T1D treatment heavily depends on multiple daily combinatorial insulin injections [24–27].”
Total Chemical Synthesis of Palmitoyl-Conjugated Insulin
Liu, M., Li, Q., Delaine, C. A., Wu, H., Arsenakis, Y., White, B. F., Forbes, B. E., Chandrashekar, C., & Hossain, M. A. (2023) · ACS Omega · doi:10.1021/acsomega.2c07918 · Cited by 2
Liu, X., Liu, F., Li, Z., Liu, X., Zhang, W., & Peng, D. (2023) · International Journal of Colorectal Disease · doi:10.1007/s00384-023-04476-9 · Cited by 2
“Insulin, including insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-II), has a metabolic effect [27].”
Recomendaciones para el uso de las insulinas en la Diabetes mellitus
Avendaño, C. R. (2022) · Revista Cubana de Alimentación y Nutrición · Cited by 2
Using Diabetes Technology in Hospitalized Patients
McCrea, D. L. (2024) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2024.07.001 · Cited by 1
The Diurnal Variation in Mitochondrial Gene in Human Type 2 Diabetic Mesenchymal Stem Cell Grafts
Horiguchi, M., Yoshihara, K., Mizukami, Y., Watanabe, K., Tsurudome, Y., & Ushijima, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020719 · Cited by 2
“The standard treatment for diabetes comprises lifestyle modifications and insulin replacement therapy [16].”
Santhanam, R., Sharma, S. K., Lomte, N., Baig, L., Kale, S., Chauthankar, S., Tawari, S., Chincholkar, S., & Jaiswal, A. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177881 · Cited by 1
Use of Insulin in Outpatient Diabetes Management
Faradji, R. N., de la Maza, E. S., Menchaca, A. P. D.-B., & Sanromán, J. R. M. (2023) · Springer eBooks · doi:10.1007/978-3-031-25519-9_37 · Cited by 2
Insulin Prodrugs with Programmed Chemical Release of an Intramolecular Cross-Link
Zaykov, A. N., Gelfanov, V. M., & DiMarchi, R. D. (2024) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-024-10660-4 · Cited by 1
“It continues to progress through chemical analogues designed to provide two types of temporal glucose management (Sims et al. 2021; Hirsch et al. 2020; Zaykov et al. 2016).”
Hjejle, S., Agesen, R. M., Thorsteinsson, B., Pedersen‐Bjergaard, U., & Brøsen, J. M. B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40153 · Cited by 1
100 Years of Insulin: A Historical Perspective
Pinto, G. B., Itabaiana, I., de Magalhães, J. L., & Antunes, A. M. D. S. (2025) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266315941241127092613 · Cited by 1
Biosimilar insulins in diabetes management: A cost-effective shift in therapeutic options
Patel, S. S. (2024) · Innovations in Pharmacy Planet · doi:10.31690/ipplanet.2024.v012i01.005 · Cited by 1
Hepşen, S., Bostan, H., Gül, Ü., Kayıhan, S., & Küçükgöde, G. E. (2025) · Endocrinology research and practice. · doi:10.5152/erp.2025.24553 · Cited by 1
Tissue-Specific Biotinylation for Interorgan Communication
Wang, Y., & Droujinine, I. A. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4694-6_15 · Cited by 1
Facile-prepared FGF21/zinc nanocomplex for efficient brain delivery in ischemic stroke treatment
Shentu, Y., Xu, M., Yin, M., Zhang, Z., Dong, Z., Lin, A., You, Z., Pan, T. S., Chen, J., Lu, Y., et al. (2025) · Nano Research · doi:10.26599/nr.2025.94907871 · Cited by 1
Current Situation on Diabetes Management: New Weapons Fighting the Disease in 2025
Okur, M. E., Miliotou, Α. N., Nitsola, V., Karantas, I. D., Okur, N. Ü., & Siafaka, P. I. (2025) · Current Drug Targets · doi:10.2174/0113894501399175250916110738 · Cited by 1
Wang, X., Hu, Y., Tang, C., Huang, C., Guo, F., & Chen, W. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.113061 · Cited by 1
Anda-Flores, Y. D., Carvajal‐Millán, E., Martínez‐Porchas, M., Rascón‐Chu, A., Martinez-Robinson, K. G., Lizardi‐Mendoza, J., Tánori, J., Martínez‐López, A. L., Garibay-Valdéz, E., & Mendez-Romero, J. I. (2025) · Polysaccharides · doi:10.3390/polysaccharides7010003 · Cited by 1
“Rats receiving subcutaneous insulin-maintained glucose levels within the physiological fasting range from 3 to 18 h post-injection, returning to hyperglycemia (158 mg/dL) by 24 h, consistent with the known pharmacokinetics of intermediate-acting insulin [62,63].”
Peña‐Rosas, U., Cuatenco, A. C., Moroni-González, D., Noriega, L., Díaz, A., Vázquez‐Roque, R. A., Brambila, E., Vergara, E. G., & Treviño, S. (2026) · Biological Trace Element Research · doi:10.1007/s12011-025-04966-7 · Cited by 1
Yu, L., Wang, F., Bao, S., Zhang, Y., Shen, X., Wang, D., Liu, Z., Liu, X.-Y., Li, L., & Gong, R. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18010097 · Cited by 1
“Insulin drugs include rapid-acting (e.g., lysergic acid and glutaraldehyde insulin), short-acting (e.g., regular human insulin), and long-acting (e.g., glycemic acid insulin) insulin preparations [8,9].”
Phan, L. P., Nguyen, T. L. L., Tran-Duc, P. N., & Heo, K. (2026) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.26.014 · Cited by 1
Holt, R. I. G., DeVries, J. H., Fischl, A. H., Hirsch, I. B., Kirkman, M. S., Klupa, T., Ludwig, B., Nørgaard, K., Pettus, J., Renard, É., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06833-z · Cited by 1
Self-citationTipi di insulina e suoi analoghi a 100 anni dalla scoperta
Toni, R. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00832-5 · Cited by 1
“le oltre 40 ore [2] che sono considerati, ad oggi, il maggio-”
BackgroundPart Two: Diabetes Part 2: A Review of Insulin Therapy in Older Patients
Phillippe, H. M., & Pogge, E. K. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.181 · Cited by 1
Evolución histórica de las moléculas de insulina empleadas en el tratamiento de la diabetes
Gomez-Perez, F. J., Cárdenas-Fragoso, J. L., Ríos-Torres, J. M., & Tovar-Méndez, V. H. (2021) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m21000017 · Cited by 1
Chast, F. (2022) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2022.04.004 · Cited by 1
Inhalation of Insulin for Diabetes Management
Bahman, F., & Taurin, S. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839165498-00165 · Cited by 1
Bhardwaj, A., Mishra, H. P., & Goel, A. (2023) · Journal of Exploratory Research in Pharmacology · doi:10.14218/jerp.2022.00063 · Cited by 1
Discharge Planning for People with Inpatient Hyperglycaemia: A Review on Pharmacological Management
Gangopadhyay, K. K., Sahay, R. K., Gupta, S., Ayyar, V. S., Das, S., Bhattacharya, S., Bhandari, S., & Bhattacharyya, A. (2023) · Current Diabetes Reviews · doi:10.2174/1573399819666230224123707 · Cited by 1
Current applications of biomolecules in biopharmaceuticals and drug discovery
Rastegari, A., Faghihi, H., & Mohammadi, Z. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91684-4.00023-2 · Cited by 1
Vangoitsenhoven, R., Narendran, P., & Mathieu, C. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch31 · Cited by 1
Insulin therapy: a century of continuing progress
Bolli, G. B., Fanelli, C. G., Lucidi, P., & Porcellati, F. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91707-0.00006-1 · Cited by 1
Shah, H. K., Shah, M. K., Patel, H., Maslekar, A. A., & Kanzariya, T. (2025) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_2_25 · Cited by 1
Diabetes mellitus: An overview
Sonia, T. A., & Sharma, C. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30272-5.00007-x · Cited by 1
Liboz, A. (2022) · theses.fr (ABES) · doi:10.70675/9abd3277zd4c4z48f5za637z73aeb8a7a807 · Cited by 1
Kim, Y. (2025) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2524129edi01 · Cited by 1
“In pediatric diabetes, long-acting insulin formulations such as insulin degludec have improved glycemic control stability as the longest-acting insulin analog while allowing for mixing with other formulations [1,2].”
Tasdemiroglu, Y. (2021) · VTechWorks (Virginia Tech)
Landmarks in Our Understanding of Insulin Synthesis Secretion and Action
Seshadri, K. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115016
“We will not also address the advances in insulin production, commercialization, modification and manufacture that are again well reviewed [3].”
Resources for Patients with Diabetes Mellitus
Ramirez, B. F. (2022) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2021.12.001
Santos, M. R., Artime, E., Duque, N., Díaz‐Cerezo, S., Spaepen, E., Carreño, Á., & Fernández, A. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01264-6
“Of the four available concentrated insulins developed to expand therapeutic options for patients, degludec U200 and lispro U200 are bioequivalent to their U100 counterpart, and glargine U300 and human U500 regular insulin are nonequivalent to a 100 U/ml reference formulation [2, 5].”
BackgroundLe récepteur de l’insuline a 50 ans – Revue des progrès accomplis
MEYTS, P. D. (2022) · Biologie Aujourd hui · doi:10.1051/jbio/2022007
“Cette réalisation a ouvert la voie au design d ’ analogues modernes recombinants de l ’ insuline aux propriétés pharmacocinétiques et pharmacodynamiques améliorées (Hirsch et al. , 2020 ; voir aussi l ’ article de Sophie Borot dans ce numéro).”
BackgroundInfluentialUlrich, W., Bielohuby, M., Korn, M., Riedel, J., Will, M., & Méndez, M. M. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14827
Successful multimodal treatment of extreme hypertriglyceridemia in a juvenile diabetic dog
Guarino, A. L., Cagle, L. A., Ehrhardt, C. M., Beatty, S. S. K., Stern, J. K., Gilor, C., Specht, A. J., & Londoño, L. (2022) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.13275
Új generációs bólusanalógok alkalmazása gyerekeknél és serdülőknél
Körner, A. (2022) · Diabetologia Hungarica · doi:10.24121/dh.2022.20
Metadata
- Authors
- Hirsch, I. B., Juneja, R., Beals, J. M., Antalis, C. J., & Wright, E. E.
- Affiliations
- University of Washington (US)
- Eli Lilly (United States) (US)
- Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California
- Charlotte Area Health Education Center, Charlotte, North Carolina
- Corresponding author
- Hirsch, Irl B
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-05-12
- Volume
- 41
- Issue
- 5
- Pages
- 733-755
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7366348
- OpenAlex
- W3024580742
- Cited by
- 237
- References
- 82
- Citations by year
- 2026: 25 · 2025: 50 · 2024: 37 · 2023: 37 · 2022: 45 · 2021: 38 · 2020: 4
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- insulin, insulin formulations, insulin analogues, rapid-acting insulin, long-acting insulin, short-acting insulin, intermediate-acting insulin, insulin mixtures, insulin levels, pharmacokinetics, pharmacodynamics, endogenous insulin, diabetes treatment, insulin replacement therapy
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.